HIVACAR aims to provide a new therapeutic alternative to “cART for life” (combined antiretroviral therapy) and will address the individual and public health limitations associated with this standard of care:
- Cost of the medication.
- Mandatory high adherence to medication for life.
- Side effects.
- Risk of resistances developement.
An innovative strategy based on the patient’s immune system, safe, affordable and scalable to achieve the functional cure of HIV-1 infection will be tested in a Phase I / IIa clinical trial. In addition, the ethical, economic and psychosocial challenges associated with a functional HIV cure will be investigated to provide a complementary alternative to the current treatment standard.
A community-led psychosocial survey about HIV remission aims to assess the knowledge and expectations among people living with HIV
Are you a person living with #HIV based in Belgium, Denmark, France or Spain? The European AIDS Treatment Group (EATG), HIV community partner within the #HIVACAR initiative, invites you to fill in ๐ ๐จ๐ช๐ง๐ซ๐๐ฎ to help better understand ๐ฎ๐ค๐ช๐ง ๐ ๐ฃ๐ค๐ฌ๐ก๐๐๐๐ ๐๐๐ค๐ช๐ฉ ๐๐๐ ๐ง๐๐ข๐๐จ๐จ๐๐ค๐ฃ...
HIVACAR aims to provide a new therapeutic alternative
Currently, over 36 million people worldwide are infected with HIV, most of them living in developing countries1. In 2014, 1.2 million people died of AIDS-related illnesses…